文献速递基础与转化研究流行病学与生物统计

抑制SLC38A2可降低高血压啮齿动物模型的血压

Inhibiting SLC38A2 lowers blood pressure in rodent models of hypertension.
PubMed 文献 · Sci Transl Med · 2025-09-03

研究鉴定钠依赖性中性氨基酸转运体SLC38A2通过调节内皮一氧化氮信号调控血压。全局及内皮细胞特异性Slc38a2敲除小鼠血压低于野生型对照,内皮NO生物合成增强。抑制剂MeAIB通过抑制内皮谷氨酰胺摄取激活AKT-eNOS通路增加NO,并在高盐和DOCA诱导的高血压小鼠及大鼠模型中降低血压。两个独立人群队列中SLC38A2 rs1873793变异在隐性模型下与高血压风险增加相关。

要点

  • 全局及内皮细胞特异性Slc38a2敲除小鼠血压低于野生型对照。
  • MeAIB抑制内皮SLC38A2,通过抑制谷氨酰胺摄取激活AKT-eNOS通路增加NO。
  • MeAIB在高盐和DOCA诱导的高血压小鼠及大鼠模型中均降低血压。

核心结论

  • 靶向SLC38A2可能成为高血压治疗的一个治疗靶点。

研究设计与样本

  • 研究采用小鼠全局及内皮细胞特异性Slc38a2基因敲除模型、单细胞RNA测序、药理学抑制剂MeAIB处理的高盐和DOCA诱导高血压小鼠及大鼠模型,以及两个独立人群队列(本课题组建立的中国队列和UK Biobank欧洲队列)进行遗传关联分析。

主要发现

  • 全局和内皮细胞特异性Slc38a2敲除小鼠(Slc38a2△EC)血压低于野生型对照。
  • 单细胞RNA测序显示Slc38a2△EC小鼠内皮细胞NO生物合成增强。
  • MeAIB通过抑制内皮细胞谷氨酰胺摄取激活AKT-eNOS通路增加NO产生。
  • MeAIB在高盐和DOCA诱导的高血压小鼠及大鼠模型中均降低血压。
  • 在两个独立人群队列中,SLC38A2 rs1873793变异在隐性模型下与高血压风险增加相关。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hypertension remains a major global health burden with limited effective treatment options. In the present study, the sodium-dependent neutral amino acid transporter SLC38A2 was identified as a regulator of blood pressure (BP) through modulating endothelial nitric oxide (NO) signaling. Here, we show that mice with global and endothelial cell (EC)-specific Slc38a2 gene knockout (Slc38a2△EC) exhibited reduced blood pressure compared with wild-type controls. Single-cell RNA sequencing analysis revealed enhanced NO biosynthesis in the ECs of the Slc38a2△EC mice. Blockade of endothelial SLC38A2 by its inhibitor methylaminoisobutyric acid (MeAIB) increased NO production through activating the protein kinase B (AKT)-endothelial NO synthase (eNOS) pathway by inhibiting EC uptake of glutamine. Moreover, MeAIB lowered blood pressure in both high-salt and deoxycorticosterone acetate (DOCA)-induced hypertensive mouse and rat models. Last, in two independent population cohorts including a Chinese cohort established by our group and a European cohort from the UK Biobank, the SLC38A2 rs1873793 variant was associated with increased risk of hypertension under a recessive model. Collectively, our findings demonstrate that targeting SLC38A2 may represent a therapeutic target for the treatment of hypertension.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Du C, Xu H, Zhao W, et al. Inhibiting SLC38A2 lowers blood pressure in rodent models of hypertension. Sci Transl Med. 2025. PMID: 40901922. doi:10.1126/scitranslmed.adt5947

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。